Data completeness
0/8 — Limited
Drug data last refreshed 53m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYCLAINE (hexylcaine hydrochloride) is a topical local anesthetic solution in pre-launch development by Merck & Co. Hexylcaine is a synthetic local anesthetic agent applied to mucosal surfaces to provide localized numbing. The mechanism involves blocking sodium channels in nerve cell membranes to prevent pain signal transmission.
Pre-Launch
Pre-launch stage indicates early-stage commercial buildout; team expansion likely for launch preparation, marketing, and field operations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CYCLAINE offers a ground-floor opportunity to build a topical anesthetic brand from pre-launch through market entry in a competitive category. This role suits professionals seeking launch experience, hands-on brand strategy, and fast-paced commercialization in a mature therapeutic area.
Brand ManagerMarket Access Manager
Worked on CYCLAINE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.